Tildipirosin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Tildipirosin: From Veterinary Respiratory Infection to Leprosy
One-Sentence Summary
Tildipirosin (DB11470) is a third-generation macrolide antibiotic approved only for veterinary use (bovine and porcine respiratory tract infections, brand name Zuprevo) and has no established human indication. The TxGNN model predicts a possible association with Leprosy, with a prediction score of 99.01%, but this is currently supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not approved for human use — veterinary indication only (bovine/porcine respiratory tract infection) |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available ([Data Gap]). Based on known information, tildipirosin is a veterinary-only macrolide antibiotic used to treat respiratory infections in cattle and pigs; it has never been used or studied in humans, and no original human indication exists to compare against.
The repurposing rationale is purely speculative: it is hypothesized that, as a macrolide-class compound, tildipirosin might share theoretical mechanistic overlap with anti-mycobacterial agents (e.g., clofazimine) that could be relevant to Mycobacterium leprae. However, there is no direct pharmacological, in vitro, or in vivo evidence that tildipirosin has activity against M. leprae. The TxGNN score reflects a graph-neural-network association only, with no mechanistic, pharmacokinetic, or safety data to substantiate it.
Given that this compound has never been evaluated in humans, any repurposing hypothesis should be treated as very early-stage and exploratory only.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
Tildipirosin is not marketed in Germany and holds no authorizations (total_licenses = 0). No product/license records are available.
Safety Considerations
Please refer to the package insert for safety information. Note: as tildipirosin is not approved for human use, no human-directed prescribing information, contraindications, or drug interaction data currently exist (TFDA warnings/contraindications: [Data Gap]; DDI query: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: There is no mechanism-of-action data, no clinical trial evidence, no published literature, and no history of human use for tildipirosin. The TxGNN score alone (L5, prediction-only) is insufficient to support any further evaluation of a leprosy indication.
To proceed, the following is needed:
- Confirmed mechanism of action (DrugBank/primary literature)
- Preclinical (in vitro/in vivo) data on activity against Mycobacterium leprae
- Any available human pharmacokinetic or toxicology data, since none currently exists for this veterinary-only compound
- TFDA/regulatory label data on warnings and contraindications, if a human formulation is ever developed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.